2-(3,4-dimethoxybenzyl)-7-((2R,3S)-2-hydroxy-6-phenylhexan-3-yl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(1H)-one

ID: ALA5268661

Chembl Id: CHEMBL5268661

Max Phase: Preclinical

Molecular Formula: C27H32N4O4

Molecular Weight: 476.58

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(Cc2nc(=O)c3c(C)nc([C@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC

Standard InChI:  InChI=1S/C27H32N4O4/c1-17-25-27(33)29-24(16-20-13-14-22(34-3)23(15-20)35-4)30-31(25)26(28-17)21(18(2)32)12-8-11-19-9-6-5-7-10-19/h5-7,9-10,13-15,18,21,32H,8,11-12,16H2,1-4H3,(H,29,30,33)/t18-,21-/m1/s1

Standard InChI Key:  MYTWFJKBZGMYCS-WIYYLYMNSA-N

Alternative Forms

  1. Parent:

    ALA5268661

    ---

Associated Targets(Human)

PDE2A Tclin Phosphodiesterase 2A (1799 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 476.58Molecular Weight (Monoisotopic): 476.2424AlogP: 3.82#Rotatable Bonds: 10
Polar Surface Area: 101.74Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 11.82CX Basic pKa: 2.23CX LogP: 3.34CX LogD: 3.34
Aromatic Rings: 4Heavy Atoms: 35QED Weighted: 0.36Np Likeness Score: -0.20

References

1. Nadur NF, de Azevedo LL, Caruso L, Graebin CS, Lacerda RB, Kümmerle AE..  (2021)  The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,  212  [PMID:33412421] [10.1016/j.ejmech.2020.113123]

Source